November 2026– date –
-
Quad-targeting CAR T cells: Phase 1 trial results for DIPG/DMG
Research Square (preprint) Overview A first-in-human phase 1 trial (BrainChild-04) demonstrated that repetitive intracerebroventricular administration of quad-targeting CAR T cells is feasible and tolerable in children and young adults w... -
MEW PCL Scaffolds: High-Density cRBC Biomanufacturing Specs
bioRxiv (preprint) Overview Researchers developed marrow-mimetic melt electrowritten (MEW) polycaprolactone (PCL) scaffolds that recapitulate erythroblastic islands to increase cultured red blood cell (cRBC) production. The platform achi... -
Morphi: AI-driven phenotypic profiling for organoid screening
bioRxiv (preprint) Overview Morphi is an AI-driven framework that infers organoid viability and phenotypic states directly from label-free bright-field microscopy. By combining viability scores with unsupervised morphology and texture fe... -
CHO Cell Bioreactor Model: Fed-batch to Continuous Transfer
bioRxiv (preprint) Overview Researchers have developed a metabolism-informed model for monoclonal antibody (mAb) production that enables the transfer of knowledge from fed-batch to continuous biomanufacturing. By embedding mass balances ... -
iPS Cell Therapy: Manufacturing Roadmap and Cost Reduction Goals
Toyo Keizai Online Japan Overview Two iPS cell-derived products for Parkinson's disease and severe heart failure received conditional and time-limited approval from Japan's Ministry of Health, Labour and Welfare in March 2026. To enable ... -
Enzell: Commercial CCPC Designation for Global CAR-T Therapy
Newspim South Korea Overview Enzell has been designated as a commercial Centralized Cell Processing Center (CCPC) by a global pharmaceutical company for CAR-T therapy production. The company has also developed a proprietary process that ... -
Samsung Biologics: Custom CMC Platform for Bispecific Antibodies
Seoul Economic Daily South Korea Overview Samsung Biologics has introduced a customized chemistry, manufacturing, and controls (CMC) platform designed to optimize the development of complex bispecific antibodies. The platform reduces the... -
CAR-T Therapy: Hong Kong Team’s 14-Day Manufacturing Timeline
BIOENGINEER.ORG China（Hong Kong） Overview Researchers in Hong Kong developed a fully automated, locally based manufacturing system that produces CD19-targeted CAR-T cell therapy in 14 days. All six pediatric patients with relapsed B-ce... -
Protonic Ceramic Electrolyzer: Doubling Hydrogen Yield from Steam
Interesting Engineering USA Overview Researchers at the University of Groningen have developed a durable ceramic electrolyzer that doubles clean hydrogen production from steam without requiring additional electricity. The cell demonstrat... -
Japan Engine Corp: Hydrogen engine for large ships and 2028 timeline
Kyodo News Japan Overview Japan Engine Corp has developed the world's first hydrogen-fueled engine for large commercial vessels, reducing CO2 emissions by over 95% compared to heavy fuel oil. The technology will undergo onboard demonstra...
